Redmile Group
VC Fund
San Francisco, United States
Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.
- Total investments:
- 207
- Last investment:
- Lead investor:
- 27%
- Fund size:
- $675M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Redmile Group invests in
Stages Redmile Group invests in
Countries Redmile Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $31M–$155M
- Series C
- $40M–$183M
- Post-IPO Equity
- $25M–$275M
Investment Focus
Industry
- Biotechnology 114 (55%)
- Health Care 82 (40%)
- Therapeutics 53 (26%)
- Medical 47 (23%)
- Pharmaceutical 39 (19%)
Stage
- Series B 46 (22%)
- Post-IPO Equity 43 (21%)
- Series C 40 (19%)
- Series A 20 (10%)
- Series D 15 (7%)
Country
- United States 104 (50%)
- United Kingdom 7 (3%)
- France 5 (2%)
- Canada 3 (1%)
- Germany 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Robert Faulkner
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Gerard van Hamel Platerink
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
|
Jeremy Green
Founder and Portfolio Manager
|
Founder and Portfolio Manager | Total investments: 1 | Find email | |
|
Mike Lee
Managing Director/Co-Founder
|
Managing Director/Co-Founder | Total investments: 0 | Find email | |
Ming Fang
Managing Director
|
Managing Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superiortherapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs. | $86.6M / Post-IPO Equity / Oct 08, 2026 | ||
| Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $66M / Series D / Aug 18, 2026 | ||
| Bios Life is a technology-enabled healthcare company built to empower individuals to proactively manage their cancer risk, redefining personalized cancer screening and survivorship. | $25M / Seed / Aug 10, 2026 | ||
| Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with newfunctions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies. | $350M / Post-IPO Equity / Aug 04, 2026 | ||
| Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $100M / Post-IPO Equity / Jun 24, 2026 | ||
| Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $110M / Post-IPO Equity / Apr 28, 2026 | ||
| Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders. | $100M / Series B / Mar 31, 2026 | ||
| ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University.This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1. | $150M / Post-IPO Equity / Jan 30, 2026 | ||
| Sensorion, a Clapiers, France-based biopharmaceutical company specifically dedicated to the development of innovative and targeted therapeutic solutions to treat vestibular deficits. | $71.5M / Post-IPO Equity / Jan 28, 2026 | ||
| Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). The Company’s developments are based on its proprietary technology for administering Cardiac Contractility Modulation therapy. This form of treatment has been shown in European clinical trials to produce an immediateand powerful modulating effect on cardiac cells, resulting in clinically meaningful increases incardiac performance.Impulse Dynamics is spearheaded by a team of professionals including, scientists, physicians, and engineers. The Company carries out research programs in major universities and hospitals throughout the world, and is currently engaged in clinical trials in Europe and in the United States. The Optimizer with Cardiac Contractility Modulation therapy, is CE marked. See Clinical Data for more information. | $158M / Dec 10, 2025 | ||
| See all 207 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Redmile Group invest in?
Redmile Group invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Post-IPO Equity stage. Most of the 207 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Redmile Group invest in?
Redmile Group typically joins rounds of $31M–$155M at Series B, $40M–$183M at Series C and $25M–$275M at Post-IPO Equity. These are whole funding-round sizes, not Redmile Group's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Redmile Group took part in.
How do I contact Redmile Group?
Public channels for Redmile Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Redmile Group?
The team at Redmile Group includes Robert Faulkner (Managing Director), Gerard van Hamel Platerink (Managing Director) and Jeremy Green (Founder and Portfolio Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
